MorphoSys AG - Report Publication Announcement 2017

News Details

Corporate | 11 April 2017 14:00

MorphoSys to Present at Upcoming Conferences (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Conference

11.04.2017 / 14:00

The issuer is solely responsible for the content of this announcement.

Planegg/Munich, Germany, April 11, 2017

MorphoSys to Present at Upcoming Conferences

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:

10 th Kempen Life Sciences Conference

Date: April 19, 2017

Venue: Amsterdam, Netherlands

Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG

UBS Global Healthcare Conference

Date: May 22/23, 2017

Venue: New York, NY, USA

Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

Berenberg European Conference

Date: May 24, 2017

Venue: Tarrytown, NY, USA

Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

A PDF version of the presentation will be provided at www.morphosys.com .

The Annual General Meeting of MorphoSys AG will take place on May 17, 2017 in Munich. A live webcast of the event and all related information are available on www.morphosys.com/agm .

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com .

HuCAL (R) , HuCAL GOLD (R) , HuCAL PLATINUM (R) , CysDisplay (R) , RapMAT (R) , arYla (R) , Ylanthia (R) , 100 billion high potentials (R) , Slonomics (R) , Lanthio Pharma (R) and LanthioPep (R) are registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG

Anke Linnartz

Head of Corporate Communications & IR

Jochen Orlowski

Associate Director Corporate Communications & IR

Alexandra Goller

Senior Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404

[email protected]

Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=YVRIABWIXH

Document title: Media Release

11.04.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


Language:	English
Company:	MorphoSys AG
	Semmelweisstr. 7
	82152 Planegg
	Germany
Phone:	+49 (0)89 899 27-0
Fax:	+49 (0)89 899 27-222
E-mail:	[email protected]
Internet:	www.morphosys.com
ISIN:	DE0006632003
WKN:	663200
Indices:	TecDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange